SCHEMBL2096107

SCHEMBL2096107

CCCOC(=O)c1ccoc1COC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.51
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
KMT2A Q03164 2/20 0.49
HPGD P15428 2/20 0.49
MEN1 O00255 1/20 0.49
NPC1 O15118 1/20 0.49
GAA P10253 1/20 0.49
TSHR P16473 6/20 0.45
TDP1 Q9NUW8 3/20 0.45
ESR1 P03372 1/20 0.45
CHRM1 P11229 1/20 0.45
SLC6A2 P23975 1/20 0.45
KDR P35968 1/20 0.45
MAOB P27338 1/20 0.44
HSD17B10 Q99714 3/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2094130 0.89 ALDH1A1 (0.56) ALDH1A1RAB9ASMN1; SMN2NPC1TSHR
SCHEMBL2096104 0.87 ALDH1A1 (0.50) ALDH1A1RAB9ASMN1; SMN2KMT2AHPGD
SCHEMBL28381382 0.78 ALDH1A1 (0.58) ALDH1A1RAB9ASMN1; SMN2KMT2AHPGD
SCHEMBL164632 0.78 ALDH1A1 (0.58) ALDH1A1RAB9ASMN1; SMN2KMT2AHPGD
SCHEMBL11669106 0.77 TP53 (0.62) ALDH1A1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL28295222 0.77 ALDH1A1 (0.53) ALDH1A1RAB9ASMN1; SMN2KMT2AHPGD
SCHEMBL2094128 0.76 TSHR (0.55) ALDH1A1RAB9ASMN1; SMN2NPC1TSHR
SCHEMBL11668571 0.76 TP53 (0.45) ALDH1A1SMN1; SMN2KMT2AMEN1NPC1
Hydrochloric Acid SCHEMBL11669190 0.76 TP53 (0.60) ALDH1A1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL28660741 0.75 ALDH1A1 (0.54) ALDH1A1RAB9ASMN1; SMN2KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 ALDH1A1 412/4885RAB9A 3153/4885SMN1; SMN2 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.